A Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Mild to Moderate Alzheimer's Disease.
- O'Brien, Terence John (Primary Chief Investigator (PCI))
Project: Research